The global Biosimilars Market , valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to ...

Endometrial Cancer is a type of cancer that begins in the lining of the uterus, most commonly affecting postmenopausal women. Rising prevalence due to increasing obesity rates and aging population, ...

LUND, SWEDEN / ACCESS Newswire / July 14, 2025 /Alligator Bioscience (Nasdaq Stockholm:ATORX) today comments on the announcement by Shanghai Henlius Biotech, Inc. that it has dosed the first patient ...

AstraZeneca spinout Dizal Pharmaceuticals won an FDA accelerated approval for sunvozertinib for previously treated EGFR ex 20 ...

GMP manufacturing completed, paediatric waiver granted, positive outcome from FDA and EMA interactions; advancing mitazalimab ...

Hong Kong-traded shares in Shanghai Fosun Pharmaceutical – which owns more than 60% of Shanghai Henlius – have trended ...

The global Biosimilars Market , valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to ...

HanchorBio signs licensing agreement with Shanghai Henlius Biotech to develop and commercialise rights to HCB101 across Greater China: Taipei, Shanghai Thursday, July 3, 2025, 11: ...

Fosun Pharma subsidiary Henlius Biotech is paying $10 million upfront for regional rights to HanchorBio’s phase 2-stage CD47 blocker.

HanchorBio Inc. (7827.TWO), a global clinical-stage biotechnology company developing innovative immunotherapies for oncology and autoimmune diseases, today announces the signing of a major out ...

HanchorBio Inc. (7827.TWO), a global clinical-stage biotechnology company developing innovative immunotherapies for oncology and autoimmune diseases, today announces the signing of a major ...

Drug maker Shanghai Henlius traces its history to 1992, when four ambitious young entrepreneurs formed Fosun Group to seize burgeoning opportunities in the early days of China’s economic reforms ...